Study Finds Psilocybin Effective and Safe for Treatment‑Resistant Major Depression

A new study examined the use of psilocybin for patients with major depression that has not responded to conventional treatments. Researchers measured both efficacy and safety outcomes in a controlled setting. The trial focused on individuals classified as treatment‑resistant. Results indicated improvements in depressive symptoms for many participants. Safety assessments reported no serious adverse events linked to the psilocybin administration. The findings suggest psilocybin may be a viable therapeutic option for this population. Authors recommend further larger‑scale trials to confirm the benefits. The study adds to growing evidence supporting psychedelic‑based therapies in psychiatry.